^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
FT555
i
Other names: FT555
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Fate Therap, J&J
Drug class:
CD38 inhibitor, NK cell stimulant, GPRC5D inhibitor
Related drugs:
2years
FT555: Off-the-Shelf CAR-NK Cell Therapy Co-Targeting GPRC5D and CD38 for the Treatment of Multiple Myeloma (ASH 2022)
Furthermore, in a distinct xenograft model of MM, treatment with FT555 resulted in significantly improved TGI against OPM2 tumor targets (FT555; 100% TGI at D51, p < 0.05). Together these studies demonstrate that FT555 is a multiplexed-engineered CAR-NK cell derived from a clonal master iPSC line, which utilizes the intrinsic versatility of NK cells to enable a highly effective combination therapy with daratumumab to simultaneously target both GPRC5D and CD38 in a single, standardized, and scalable off-the-shelf platform.
IO biomarker
|
NCAM1 (Neural cell adhesion molecule 1) • GPRC5D (G Protein-Coupled Receptor Class C Group 5 Member D) • IL15 (Interleukin 15)
|
CD38 expression
|
Darzalex (daratumumab) • FT555
Share via
